Investment Pitches

Pitch Summary:
SDI Group was purchased before the imposition of tariffs, and it performed well during market downturns. The decision to sell was made to reallocate capital to other opportunities that had experienced significant declines.

BSD Analysis:
SDI Group's performance during the tariff-induced volatility demonstrated resilience, but the decision to exit was driven by a strategic reallocation to potentially undervalued assets. The company's focus on scientific and technology products positions it well in a growing industry, but the market's reaction to tariffs provided a unique opportunity to capture gains and reinvest in more promising ventures. The decision reflects a broader strategy of leveraging market volatility to optimize portfolio returns. While SDI Group has shown strong performance, the potential for higher returns in other sectors, especially those hit harder by tariffs, justified the reallocation. This approach aligns with a dynamic investment strategy that prioritizes flexibility and responsiveness to market conditions.

Pitch Summary:
Centene Corp. has experienced a dramatic decline in stock price due to a combination of regulatory challenges and a significant actuarial error. Despite these setbacks, the company's robust balance sheet and historical profitability suggest resilience. The stock's current valuation appears depressed, offering potential upside as management can leverage its share repurchase program to capitalize on the low stock price. Additionally, the company's ability to reprice premiums and its strategic asset management provide a margin of safety.

BSD Analysis:
Centene's financial health is underpinned by a strong investment portfolio and a strategic approach to debt management, with a total debt of $18.5 billion at favorable fixed rates. The company's return on equity has averaged 13.4% over the past decade, indicating efficient capital use. Despite a recent $1.8 billion hit from risk-adjusted payment adjustments, Centene's long-term investments and cash reserves provide a buffer against short-term volatility. The political landscape poses risks, particularly with potential Medicaid cuts under the OBBBA, but the stock's low valuation, trading at an EV/FCF multiple of 4.7, suggests that much of the downside is already priced in. Notably, prominent investors like David Einhorn and Bill Nygren have shown confidence in Centene by purchasing shares, indicating potential for recovery and growth.

Pitch Summary:
Cewe is a leading European photo service and online printing company, recognized for its stable and predictable business model. The company has consistently increased its revenue and EBIT margin over the years, with a moderate but steady growth rate. Despite its strong fundamentals, Cewe's stock is undervalued, trading at a low EV/EBIT multiple. The company's ongoing dividend increases and share buybacks enhance shareholder returns, making it an attractive defensive investment with a favorable risk-reward profile.

BSD Analysis:
Cewe's resilience and consistent performance make it a standout in the photofinishing and online printing industry. The company's strategic focus on its core products and services has driven steady revenue growth, even during challenging market conditions. With a strong cash position, Cewe is well-positioned to continue its dividend policy and share buyback program, further boosting shareholder value. The current undervaluation presents a compelling opportunity for investors seeking a stable, income-generating investment in a defensive sector.

Pitch Summary:
HBM Healthcare Investments is a Swiss firm investing in both public and private healthcare companies, with a strong track record of NAV growth. Despite a challenging market environment, HBM has maintained a diversified portfolio with a focus on profitable companies. The stock is currently trading at a 25% discount to NAV, offering a potential upside as the firm continues its share buyback program. HBM's conservative valuation approach and strategic long-term investments in diverse healthcare sectors position it well for future growth.

BSD Analysis:
HBM Healthcare's expertise in the healthcare sector, combined with its diversified investment strategy, provides a solid foundation for long-term growth. The company's focus on both public and private investments allows it to capitalize on emerging trends in biotech, medtech, and digital health. With a strong cash position and ongoing share buybacks, HBM is well-equipped to navigate market volatility. The current discount to NAV presents an attractive entry point for investors seeking exposure to the healthcare sector's potential recovery.

Pitch Summary:
Molten Ventures is a leading venture capital firm in the UK, with a strong track record of investing in prominent European startups. The firm has a diversified portfolio valued at £1.37 billion, with Revolut being its largest holding. Despite a conservative approach to valuation adjustments, Molten has consistently delivered returns exceeding its target of 20% annually, achieving an average of 28% since its IPO in 2016. The stock is currently trading at a significant discount to its Net Asset Value (NAV), presenting a potential opportunity for investors as market sentiment improves.

BSD Analysis:
Molten Ventures' conservative valuation approach, particularly in not prematurely adjusting valuations upwards, sets it apart from other VCs. This prudence, coupled with strategic share buybacks, positions the firm well for future growth. The current market sentiment has led to a significant discount in its stock price relative to NAV, which could narrow as investor confidence returns. With a robust portfolio and a focus on later-stage investments, Molten is well-positioned to capitalize on a potential resurgence in the startup ecosystem, especially as interest rates stabilize and funding programs in Europe gain traction.

Pitch Summary:
The author presents Civeo as an activist-driven opportunity combining hidden asset value, earnings growth, and aggressive buyback-led capital returns. Engine Capital has already pushed management toward a 20% repurchase authorization and could drive a tender offer. Underutilized Canadian assets offer embedded EBITDA optionality, while Australian operations grow under long-term contracts. Trading at ~5× forward EBITDA, CVEO appears inexpensive vs peers. Conservative estimates suggest 40% upside, with activist assumptions implying 100%+ potential.

BSD Analysis:
Civeo benefits from contracted, stable demand tied to long-life resource projects while activist involvement raises the likelihood of disciplined capital allocation. The authorized 20% buyback is highly accretive given valuation, and a tender offer would accelerate returns. Underutilized Canadian assets offer meaningful operational leverage if redeployed or sold. Asset intensity limits flexibility, but Australian operations provide growth and diversification. Overall, the setup reflects a classic special situation where activism, valuation, and latent asset value create asymmetric upside.

Actual Post Content:
Interesting setup over at $CVEO with a highly reputable activist involved. At its core, the pitch rests on a combination of hidden assets, growing earning power, and the presence of a reputable activist, Engine Capital (which owns 10%), already driving significant changes in capital allocation. My conservative estimate of upside, excluding the value of underutilized assets, suggests a 40% gain over 2.5 years, compared to Engine Capital’s estimate of 100%+ over the same period. A key aspect of the thesis is the ongoing capital return program. Engine Capital began its campaign in March 2025, pushing management to pivot away from dividends toward aggressive share repurchases. This led to a newly authorized plan to buy back up to 20% of outstanding shares. In the Q1 2025 call, management explicitly kept the door open for an expedited tender offer (as proposed by Engine), which could significantly accelerate value realization given the company’s thin float and tightly held shareholder base (with 40% owned by 3–4 large shareholders). Additionally, with 100% of free cash flow earmarked for buybacks, transitioning to 75% once the 20% repurchase target is reached, the capital return story is front-loaded here. CVEO operates workforce lodges and mobile camps primarily in Canada and Australia, serving resource companies in remote areas. Its asset-heavy Canadian operations have underutilized capacity that could either be repurposed or sold, while its Australian, asset-light services segment is on a solid growth trajectory, backed by multi-year contracts. The Canadian assets are currently at a cyclical low in utilization, but could be reactivated quickly if demand returns or sold otherwise. In late 2023, CVEO sold one of its Canadian lodges (McClelland Lake) for $33m. At their peak in 2022, underutilized assets were generating between $20–36m in EBITDA, compared to the expected 2025 EBITDA of $97m. Any new contracts for these idle assets would materially enhance the company’s earning power. Valuation-wise, CVEO trades at just 5x forward EBITDA (including the recent acquisition), compared to peers trading at 5.5–7.5x. This is particularly attractive given the stability of its long-term contracts, the expansion potential in Australia, and the likelihood of further cost reductions in Canada (large overhead that could be eliminated). Using a conservative estimate of $102m in 2027 EBITDA—and assuming only the currently authorized 20% buyback—the base case implies ~40% upside. Engine Capital’s more aggressive buyback assumptions yield potential upside of over 100%. Finally, CVEO is not overly exposed to commodity price swings with its current asset base. Its Canadian segment is anchored by long-life oil sands maintenance projects, while its Australian business benefits from tight labor markets and long-term contracts with metallurgical coal miners.

URL: https://x.com/InvestSpecial/status/1945406803250122943

Pitch Summary:
Booking Holdings has applied OpenAI’s large language model to its data systems to advance a long-held strategic vision that it calls the “connected trip,” a more seamless and intuitive way for users to book and manage their itineraries. The company has made significant progress, with travelers now able to reserve and keep track of flights, hotels, car rentals and local experiences in one platform. AI helps travelers create customized itineraries and supports hotel partners through automated responses and improved onboarding. Connected trip transactions grew 35% year over year. Booking continues to strengthen engagement, reduce reliance on Google, and streamline user experience through AI-driven personalization and workflow enhancements.

BSD Analysis:
Booking is an oligopolist in online travel whose colossal cash flow and dominant scale are being unfairly penalized by the market's irrational fear of AI competition. The core thesis is that GenAI adoption by consumers is a net benefit, not a threat, as it accelerates the search-to-booking conversion, funneling massive volume toward the platform that has the broadest supply. Booking's 2.8 million hotel listings give it an unassailable supply moat that competitors, even Google's new AI travel tool, must rely on for booking fulfillment. The recent stock dip following Google's AI launch represents an excellent entry point, as the market confuses the new competitive front with genuine structural failure. The company’s unique agency model is capital-light and generates superior Free Cash Flow (FCF), which management is aggressively deploying through share buybacks to amplify per-share growth.

Pitch Summary:
Shares of Adobe have struggled in 2025, as investors continue to worry about rising competition from user-friendly platforms such as Canva and the disruptive potential of AI-powered image- and video-generation tools such as DALL-E and Sora. These fears overshadowed the company’s strong second-quarter results: Adobe beat expectations across the board, with revenue and adjusted earnings up 11% and 13% year over year, respectively, and better-than-estimated performance in key operating metrics such as annual recurring revenue from digital media, which rose 12% in constant-currency terms. Management modestly raised its full-year outlook, despite prevailing macroeconomic concerns. Nonetheless, the market remained unconvinced, and the stock fell after the earnings report. The irony is that the very force investors worry will threaten Adobe’s dominance may instead become its greatest source of growth. AI models are very likely to lead to an even larger explosion in visual content, as more people are equipped to create art faster—simply by entering a series of prompts. Raw output needs to be edited, customized to meet brand standards, and integrated into larger workflows—where Adobe shines. New subscribers to Firefly grew 30% quarter over quarter, and Adobe Express added 8,000 new customers. With 700 million monthly active users and deep workflow integration, Adobe remains the essential editing layer in the AI era.

BSD Analysis:
Adobe is a brutally undervalued AI powerhouse whose stock decline is a massive market misjudgment, ignoring its unassailable competitive moat and unique monetization strategy. The core thesis is a successful pivot to GenAI through Firefly and AI Foundry, which is leveraging its proprietary, commercial-safe training data (licensed assets) to gain a powerful advantage over open-source rivals in the enterprise. This "commercial-safe" status is the ultimate key to unlocking new, defensible revenue streams by eliminating corporate copyright infringement risk. Management is further accelerating this shift by allowing enterprises to build custom generative AI models on their own intellectual property via the new AI Foundry service. Despite a −27.5% one-year shareholder return, the stock is priced at a deep discount—up to 16.4% undervalued—implying the market is missing the key drivers of enterprise AI adoption. Adobe's strategic bets and expanding AI ecosystem continue to shape the long-term outlook, making the recent selloff a rare buying opportunity ahead of its next earnings inflection.

Pitch Summary:
MercadoLibre has taken the best of what other online retailers do, tailored it for its own local markets, and added innovative new services. For instance, in a region with many “unbanked” customers, it built its own payments service and became a leader in digital payments. It then built up a credit business by offering services to customers when banks wouldn’t extend them credit; the retailer has been able to assess borrower risks using both payments and sales data it collects from customers. Another advantage is more physical. In the US, retailers can rely on well-established independent carriers such as FedEx or UPS for deliveries. Not only do those services not exist in large swaths of Latin America, in many places paved roads don’t even exist. MercadoLibre’s solution was to invest billions in its own distribution networks, including physical delivery to the most remote locations. Its own managed logistics network handles 95% of its shipments, and half of those parcels arrive the same or the next day after an order is placed. Much like Amazon’s Prime, it has created its own loyalty program, Meli+, that bundles all these services and offerings to create a compelling user experience. While the competitive landscape is evolving rapidly, MercadoLibre’s deep knowledge of its local customer base, integrated ecosystem, and focus on innovation are its long-term competitive advantages.

BSD Analysis:
MercadoLibre is Latin America’s flagship digital platform — part Amazon, part PayPal, part FedEx — and its ecosystem advantages deepen every year. Mercado Pago has become a financial network of its own, often outgrowing commerce. Logistics investments give MELI the fastest and most reliable delivery in the region, which competitors can’t replicate without burning oceans of capital. The company manages to grow at high double digits while still expanding margins, an almost impossible feat in emerging markets. Macroeconomic volatility is constant, yet MELI’s execution transcends it. Galperin’s leadership and culture of relentless reinvestment remain core differentiators. This is one of the strongest platform flywheels in the world.

Pitch Summary:
We’ve fully exited our position in Globant following the company’s weaker-than-expected Q1 2025 earnings report and disappointing FY25 revenue guidance. While the company has managed to maintain outsized revenue growth relative to its IT services peers for several quarters, recent guidance projecting low single-digit revenue growth for FY25 brings its outlook roughly in line with the peer group. This outcome speaks to the more protracted IT services spending weakness that may continue, and the potentially more discretionary nature of Globant’s business model (which is heavily consulting-based and less reliant on multi-year outsourcing contracts than many larger competitors). Globant may be worth revisiting at a later date, if and when growth reaccelerates. For now, however, we see better risk / reward opportunities elsewhere.

BSD Analysis:
Globant is a high-growth digital transformation specialist whose nearshore, studio-based model provides a superior, non-replicable competitive moat. The core thesis is a conviction bet on the relentless, non-discretionary corporate need to reinvent and become agile using technology, especially in AI. The company's unique structure—a globally cohesive team of over 23,500 creative minds serving 1,100 blue-chip clients—allows it to deliver superior service quality, evidenced by its Net Promoter Score (NPS) of 64. Globant consistently delivers strong financial results, including 59.3% year-over-year revenue growth in 2021. The company is positioned as an indispensable partner for major brands undergoing complex reinvention, justifying its premium valuation.

Pitch Summary:
We initiated a position in IDEXX Labs, a global leader in pet diagnostics, offering in-clinic diagnostics via a razor-and-blades business model—selling instruments and recurring consumables—as well as out-of-clinic reference lab services. We have researched the business for two decades and admired its durable competitive advantages, highly recurring and profitable business model, attractive runway, supported by tailwinds from pet ownership and the “humanization of pets,” and solid execution by its management team. IDEXX employs a successful "surround the customer" strategy by offering diagnostic tests across many modalities, along with imaging and veterinary practice management software. With a dominant market share in pet diagnostic tests, IDEXX continues expanding its addressable market by innovating new testing types and creating additional revenue streams for its veterinary customers. We envision many years of continued innovation and market expansion, with minimal competitive threat. Historically, we questioned IDEXX's persistently high valuation. However, the recent transitory business slowdown—driven by fewer vet clinic visits as COVID-era pets remain relatively young—has made the valuation more attractive. We believe the company’s long-term outlook remains essentially unchanged. As these pets approach 6-7 years of age, their vet care needs will increase, supporting our expectation for sustained double-digit organic revenue growth and mid-to-high teens EPS growth at least in line with the portfolio average. We expect IDEXX to exhibit safety-like characteristics due to its unique competitive position, recurring revenue stream, and loyal shareholder base.

BSD Analysis:
IDEXX is the unassailable, high-growth oligopolist in veterinary diagnostics, whose premium valuation is justified by its superior, non-cyclical growth in the Companion Animal Group (CAG). The core thesis is a conviction bet on the "humanization of pets" and the resulting Diagnostic Advantage—a uniquely competitive "razor and blade" business model where diagnostic analyzers (the "razor") drive long-term demand for high-margin consumables (the "blade"). The financial performance is ruthless: Q3 2025 revenue surged 13% and comparable EPS rose 15%, powered by an impressive 14% organic growth in International CAG Diagnostics recurring revenue. This relentless growth is fueled by a 71% organic expansion in CAG Diagnostics capital instrument revenues in Q3 2025. The stock is a proven compounder, turning a $1,000 investment ten years ago into $10,653.46—a 965.35% gain that crushes the S&P 500's return of 227.69% over the same period. IDEXX is an indispensable, high-quality play on the non-cyclical, long-term structural growth of pet healthcare.

Pitch Summary:
We have reestablished our position in Starbucks, now under the leadership of newly appointed CEO Brian Niccol, formerly of Chipotle. Niccol has articulated a clear, multi-pronged turnaround plan that we view as both practical and achievable. We believe Starbucks’ store operations became overly complex, resulting in over-tasked baristas and a poor customer experience. Having successfully revitalized Chipotle, we view Niccol as the right leader for Starbucks. He has already identified fixes for in-store operations, marketing, and customer service that we believe can potentially result in meaningful impact in the not-too-distant future, provided they are effectively scaled across 17,000 U.S. stores. We believe Starbucks retains an aspirational brand and a loyal customer base. As such, we see solid growth ahead through store productivity, new-store growth, and significant margin expansion. After a few years of mismanagement and a languishing stock, we expect considerable upside for this iconic brand.

BSD Analysis:
Starbucks is a global lifestyle brand oligarch whose future is a leveraged bet on its massive expansion into the Chinese market and its digital ecosystem. The core thesis is a surgical, strategic pivot: Starbucks sold a majority stake in its China retail operations to a Chinese investment firm to accelerate growth into smaller cities and emerging regions. This joint venture, valued at over $13 billion, aims to expand the store footprint to as many as 20,000 locations over time. This localized partnership mirrors McDonald's successful strategy and will help optimize store locations, localize products, and enhance brand competitiveness. This is a high-conviction bet on the long-term, structural growth of the Chinese specialty coffee market, which is forecast to rise to 273.9 billion yuan ($18.6 billion) by 2029.

Pitch Summary:
AI re-emerged as the dominant narrative, driving much of the market’s leadership in the second quarter. Oracle was our top-owned relative contributor, up 56% in the quarter (and 76% since the market bottom on April 9) as the market embraced a meaningful acceleration in growth driven by the Oracle Cloud Infrastructure (OCI) segment. The company appears to be in the early stages of a significant revenue growth increase, fueled partly by its position as a go-to cloud infrastructure provider for training generative AI models. This is only one facet of the investment thesis. Oracle has been successfully migrating enterprise software customers to the cloud as well and is, for the first time, able to finally bring its database clients to the cloud, creating a multi-pronged growth investment thesis. As the air came out of many perceived “AI beneficiaries” amidst elevated tariff-related uncertainty in 1Q, we noted in our previous Quarterly Letter that this had pressured Oracle shares. We took advantage of this weakness by adding to our position in 1Q and again in 2Q, making it one of our largest portfolio weightings.

BSD Analysis:
Oracle is the ruthless, deeply leveraged AI infrastructure pure-play whose stock is trading at a massive discount, creating a volatile but high-conviction entry point. The core thesis is a structural pivot to the Cloud Infrastructure (OCI) business, which management is aggressively positioning to hit $144 billion in revenue by FY2030. This growth is fueled by its massive commitments to AI, including making NVIDIA's most powerful H100 AI processors available on its cloud infrastructure and partnering with companies like Cohere to embed Generative AI capabilities into its applications. OCI offers Generative AI features, including the deployment of Google Gemini models and the beta launch of Agent Hub for creating and deploying AI agents. The critical signal is the 359% surge in its contract backlog (RPO) to $455 billion in Q1 FY2026, which signals durable, long-term commitment from corporate clients. Critics are fixated on the high financial leverage, with the Debt-to-Equity ratio at 436% to 500%—which is much higher than its AI peers—but this is the cost of securing a generational, trillion-dollar market through aggressive CapEx. The company is converting its legacy software dominance into the physical infrastructure required to win the American AI race, a high-stakes bet with no in-between.

Pitch Summary:
NOF is a Japanese company with a compelling investment profile: a stable, cash-generative core business in functional chemicals, supported by high-growth segments in cosmetics and pharmaceuticals. These segments are driving both top-line expansion and margin improvement. Despite this favorable mix, the company continues to trade like a basic chemicals business at just 17x earnings. With leading market positions in faster-growing, higher-margin niches, we believe NOF is well-positioned to deliver double-digit growth for years to come, and that the market has yet to fully reflect this structural shift in its valuation. In the near term, cosmetic surfactants – which account for approximately 20% of NOF’s sales and 25% of profits – are poised to drive meaningful upside, following a recent doubling of production capacity. NOF operates as an original design manufacturer (ODM) for leading cosmetic brands, including Ryohin Keikaku (popularly known as Muji). The cosmetics segment grew 36% last year, fueled by Ryohin’s success and continued store expansion, particularly in China. With sustainable double-digit revenue growth and operating margins of 25% or higher, the cosmetics business is well-positioned to support 1–2% annual expansion in group-level margins over the next few years – a key driver of long-term value creation. NOF also has clear visibility into long-term, sustainable growth through its Pharmaceutical and Drug Delivery Systems (DDS) platform, which now accounts for about 20% of sales and 35% of profits. Like the cosmetics segment, DDS recently doubled its production capacity to support future demand. The company holds a 60% global market share in polyethylene glycol (PEG) – a key drug additive that enhances stability and prolongs therapeutic effects. In addition, NOF is rapidly scaling its capabilities in lipid nanoparticles, a critical delivery technology for nucleic acid-based therapies (RNA, DNA) and other next-generation treatments. While still in the early stages, the lipid nanoparticle market is projected to grow at a 40% annual rate, positioning NOF to benefit from secular growth well into the 2030s. A final growth catalyst lies in NOF’s explosives division, which represents approximately 10% of sales and holds a 100% market share in Japan for rocket propellants used by the Self-Defense Forces (SDF). While the company provides limited disclosure on this segment, it recently announced a doubling of capacity to meet rising demand. However, with captive customers like IHI ramping up missile and rocket production by several multiples, even this expansion is unlikely to fully meet growing needs – suggesting continued upside and strategic importance for this niche, high-barrier business. NOF is also making encouraging progress on corporate governance. While the introduction of a formal Investor Relations function and explicit shareholder return policies may seem like modest steps, they represent meaningful improvements for the company. With only two analysts currently covering what is otherwise a well-established “mid-cap” company, we believe there is still significant discovery and re-rating potential as governance standards improve and investor visibility increases.

BSD Analysis:
NOF is riding twin secular trends: the biologics explosion and the demand for specialty materials in semiconductors and coatings. Its diversified portfolio makes it resilient, while its deep pharma ties give it pricing power. Investors still treat it like a mundane chemicals company — but NOF is a global advanced-materials supplier with real growth.

Pitch Summary:
Magnite is one of the largest independent sell-side platforms (SSPs) – effectively serving as enterprise software for digital publishers, including websites and connected TV channels. Its platform enables publishers to manage ad serving, optimize yield, and target audiences more effectively by connecting their ad inventory to a broad network of demand partners. In return, SSPs earn a percentage of ad spend flowing through their platforms. Magnite benefits from deep integrations with publishers and demand-side platforms, creating high switching costs and a durable competitive moat. The company is widely recognized for its fast, reliable technology infrastructure. Two major trends are reshaping the digital advertising landscape. First, ad budgets continue to shift from traditional linear TV to Connected TV (CTV) as platforms like Netflix and others expand their ad-supported offerings. Second, a recent antitrust ruling against Google may significantly alter the dynamics of the open web advertising market – specifically for video and display ads on browser-based websites. The court found Google had engaged in anti-competitive practices, and a follow-up hearing this September could result in structural changes that benefit independent ad tech providers. CTV now represents approximately 50% of Magnite’s revenue, with the segment expected to grow at a 15% CAGR over the medium term. The company is well-positioned to outpace this growth thanks to their scale, deep publisher relationships, and strong technology platforms. In mid-2024, Magnite was named Netflix’s exclusive ad tech partner, positioning it to benefit as Netflix targets $9 billion in ad revenue by 2030. In the open web advertising market, Google maintains a dominant 60% share, compared to 7% for Magnite. Despite its relatively small share, open web ads still account for approximately 40% of Magnite’s revenue. A meaningful shift in market share following the recent antitrust ruling could serve as a powerful catalyst, with potential double-digit revenue growth beginning in 2026. To illustrate the upside: each 1% shift in market share away from Google would translate into an estimated $50–75 million in high-margin revenue (with about 90% incremental margin) – equivalent to roughly half of Magnite’s 2024 EBITDA. At current valuations – 15x forward EBITDA for Magnite – we believe this embedded optionality is not yet priced in, and the stocks could offer 50–100% upside from current levels.

BSD Analysis:
Magnite is the DSP alternative that’s benefiting from fragmentation of the streaming ecosystem. As every platform launches or expands ad tiers, supply-side partners become more important, and Magnite is already embedded. The company has cleaned up its cost structure, boosted ad quality, and strengthened its pipeline in CTV. This is a levered bet on the future of programmatic TV — and it’s still early.

Pitch Summary:
NOF is a Japanese company with a compelling investment profile: a stable, cash-generative core business in functional chemicals, supported by high-growth segments in cosmetics and pharmaceuticals. These segments are driving both top-line expansion and margin improvement. Despite this favorable mix, the company continues to trade like a basic chemicals business at just 17x earnings. With leading market positions in faster-growing, higher-margin niches, we believe NOF is well-positioned to deliver double-digit growth for years to come, and that the market has yet to fully reflect this structural shift in its valuation. In the near term, cosmetic surfactants – which account for approximately 20% of NOF’s sales and 25% of profits – are poised to drive meaningful upside, following a recent doubling of production capacity. NOF operates as an original design manufacturer (ODM) for leading cosmetic brands, including Ryohin Keikaku (popularly known as Muji). The cosmetics segment grew 36% last year, fueled by Ryohin’s success and continued store expansion, particularly in China. With sustainable double-digit revenue growth and operating margins of 25% or higher, the cosmetics business is well-positioned to support 1–2% annual expansion in group-level margins over the next few years – a key driver of long-term value creation. NOF also has clear visibility into long-term, sustainable growth through its Pharmaceutical and Drug Delivery Systems (DDS) platform, which now accounts for about 20% of sales and 35% of profits. Like the cosmetics segment, DDS recently doubled its production capacity to support future demand. The company holds a 60% global market share in polyethylene glycol (PEG) – a key drug additive that enhances stability and prolongs therapeutic effects. In addition, NOF is rapidly scaling its capabilities in lipid nanoparticles, a critical delivery technology for nucleic acid-based therapies (RNA, DNA) and other next-generation treatments. While still in the early stages, the lipid nanoparticle market is projected to grow at a 40% annual rate, positioning NOF to benefit from secular growth well into the 2030s. A final growth catalyst lies in NOF’s explosives division, which represents approximately 10% of sales and holds a 100% market share in Japan for rocket propellants used by the Self-Defense Forces (SDF). While the company provides limited disclosure on this segment, it recently announced a doubling of capacity to meet rising demand. However, with captive customers like IHI ramping up missile and rocket production by several multiples, even this expansion is unlikely to fully meet growing needs – suggesting continued upside and strategic importance for this niche, high-barrier business. NOF is also making encouraging progress on corporate governance. While the introduction of a formal Investor Relations function and explicit shareholder return policies may seem like modest steps, they represent meaningful improvements for the company. With only two analysts currently covering what is otherwise a well-established “mid-cap” company, we believe there is still significant discovery and re-rating potential as governance standards improve and investor visibility increases.

BSD Analysis:
NOF’s dominance in high-purity chemicals and biologic drug components makes it irreplaceable to pharma giants who require reliability and consistency. Demand for advanced controlled-release and lipid-based drug delivery keeps climbing, and NOF owns that niche. With expanding semiconductor-materials demand and elite margins, NOF is one of Japan’s quietest, highest-quality industrial-science hybrids.

Pitch Summary:
Magnite is one of the largest independent sell-side platforms (SSPs) – effectively serving as enterprise software for digital publishers, including websites and connected TV channels. Its platform enables publishers to manage ad serving, optimize yield, and target audiences more effectively by connecting their ad inventory to a broad network of demand partners. In return, SSPs earn a percentage of ad spend flowing through their platforms. Magnite benefits from deep integrations with publishers and demand-side platforms, creating high switching costs and a durable competitive moat. The company is widely recognized for its fast, reliable technology infrastructure. Two major trends are reshaping the digital advertising landscape. First, ad budgets continue to shift from traditional linear TV to Connected TV (CTV) as platforms like Netflix and others expand their ad-supported offerings. Second, a recent antitrust ruling against Google may significantly alter the dynamics of the open web advertising market – specifically for video and display ads on browser-based websites. The court found Google had engaged in anti-competitive practices, and a follow-up hearing this September could result in structural changes that benefit independent ad tech providers. CTV now represents approximately 50% of Magnite’s revenue, with the segment expected to grow at a 15% CAGR over the medium term. The company is well-positioned to outpace this growth thanks to their scale, deep publisher relationships, and strong technology platforms. In mid-2024, Magnite was named Netflix’s exclusive ad tech partner, positioning it to benefit as Netflix targets $9 billion in ad revenue by 2030. In the open web advertising market, Google maintains a dominant 60% share, compared to 7% for Magnite. Despite its relatively small share, open web ads still account for approximately 40% of Magnite’s revenue. A meaningful shift in market share following the recent antitrust ruling could serve as a powerful catalyst, with potential double-digit revenue growth beginning in 2026. To illustrate the upside: each 1% shift in market share away from Google would translate into an estimated $50–75 million in high-margin revenue (with about 90% incremental margin) – equivalent to roughly half of Magnite’s 2024 EBITDA. At current valuations – 15x forward EBITDA for Magnite – we believe this embedded optionality is not yet priced in, and the stock could offer 50–100% upside from current levels.

BSD Analysis:
Magnite’s real competitive advantage isn’t scale — it’s neutrality. As streaming platforms shift to ad-supported tiers, they need partners they can trust with auction dynamics and transparency. Magnite fills that role perfectly. With device-level CTV growth accelerating, Magnite is positioned directly in front of the next wave of premium programmatic monetization. The market still prices it like a flaky ad-tech small cap — but the runway is long and the model is getting sturdier.

Pitch Summary:
NOF Corporation (Japan – $4.6 billion market cap). NOF is a Japanese company with a compelling investment profile: a stable, cash-generative core business in functional chemicals, supported by high-growth segments in cosmetics and pharmaceuticals. Despite this favorable mix, the company continues to trade like a basic chemicals business at just 17x earnings. In the near term, cosmetic surfactants – which account for approximately 20% of NOF’s sales and 25% of profits – are poised to drive meaningful upside, following a recent doubling of production capacity. The cosmetics segment grew 36% last year, fueled by Ryohin’s success and continued store expansion. NOF also has clear visibility into long-term growth through its Pharmaceutical and Drug Delivery Systems (DDS) platform, which now accounts for about 20% of sales and 35% of profits. The company holds a 60% global market share in polyethylene glycol (PEG) and is scaling rapidly in lipid nanoparticles for next-generation therapies. A final growth catalyst lies in NOF’s explosives division, which holds a 100% domestic market share in rocket propellants for the Self-Defense Forces, with capacity recently doubled to meet rising demand. Management is also making progress on governance and investor communication, increasing discovery and re-rating potential.

BSD Analysis:
NOF is the Japanese specialty-chemicals giant powering everything from biologics manufacturing to electronic materials, surfactants, and advanced polymers. Its PEGylation and lipid delivery technologies make it a hidden enabler of next-gen therapies and mRNA drugs. Margins are steady, R&D depth is underrated, and global expansion into pharma ingredients gives NOF multi-year growth visibility. This is a quiet compounder the market chronically underprices.

Pitch Summary:
Magnite, Inc. (U.S. – $3 billion market cap). Magnite is one of the largest independent sell-side platforms (SSPs) – effectively serving as enterprise software for digital publishers, including websites and connected TV channels. Its platform enables publishers to manage ad serving, optimize yield, and target audiences more effectively by connecting their ad inventory to a broad network of demand partners. In return, SSPs earn a percentage of ad spend flowing through their platforms. Magnite benefits from deep integrations with publishers and demand-side platforms, creating high switching costs and a durable competitive moat. Two major trends are reshaping the digital advertising landscape. First, ad budgets continue to shift from traditional linear TV to Connected TV (CTV) as platforms like Netflix and others expand their ad-supported offerings. Second, a recent antitrust ruling against Google may significantly alter the dynamics of the open web advertising market – specifically for video and display ads on browser-based websites. CTV now represents approximately 50% of Magnite’s revenue. The company is well-positioned to outpace this growth thanks to their scale, deep publisher relationships, and strong technology platforms. In mid-2024, Magnite was named Netflix’s exclusive ad tech partner. In the open web advertising market, Google maintains a dominant 60% share, compared to 7% for Magnite. A meaningful shift in market share following the recent antitrust ruling could serve as a powerful catalyst, with potential double-digit revenue growth beginning in 2026. Each 1% shift in market share away from Google would translate into an estimated $50–75 million in high-margin revenue.

BSD Analysis:
Magnite is the independent ad-tech platform riding the shift toward CTV and premium programmatic — a space where advertisers want alternatives to walled gardens. Revenue is stabilizing, CTV spend is rising, and Magnite’s supply-path optimization capabilities give it real strategic relevance. The balance sheet is improving, margins are firming, and the worst of the post-pandemic ad slump appears behind it. Magnite remains one of the few scaled independents positioned to benefit from the secular growth of programmatic.

Pitch Summary:
Ziff Davis (ZD) is a diversified digital media and internet services company trading at just 4× EBITA and under 6× earnings despite strong free cash flow generation and disciplined capital allocation. The business spans five verticals—Technology & Shopping, Gaming & Entertainment, Health & Wellness, Connectivity, and Cybersecurity & Martech—supported by recurring B2B and subscription revenue streams. With $1.4B in 2024 revenue, $494M EBITDA, and $374M EBIT, the company trades at an EV of ~$1.6B, implying a 10–12% FCF yield and substantial margin of safety. Management has repurchased 10% of shares at ~$50/share, maintains low leverage, and has a clear 20% ROIC hurdle for acquisitions.

BSD Analysis:
Ziff Davis is a misunderstood collection of durable niche digital brands with recurring cash flow, disciplined management, and significant buyback support. Despite investor skepticism toward legacy digital publishers and AI’s impact on web traffic, ZD’s diversified assets (e.g., PCMag, IGN, Speedtest, Everyday Health, Vipre) benefit from unique data and subscription-based models, reducing exposure to search-driven traffic. CEO Vivek Shah has consistently executed value-accretive M&A and returned cash to shareholders, producing steady EPS growth. The stock’s extreme valuation discount (4× EV/EBITA, 2.8× EBITDA) is unjustified given its 25–35% margins, strong balance sheet, and capital discipline. Upside could be realized through ongoing buybacks, sum-of-the-parts recognition, or a strategic sale.